Hepatitis C prevalence among australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s

Medical Journal of Australia

Volumn 172, Issue 12, 2000, Pages 588-591

  Freeman, Anthony J ^a   Zekry, Amany ^a   Whybin, L Ross ^a   Harvey, Charles E ^a   Van Beek, Ingrid A ^b   De Kantzow, Sophie L ^a   Rawlinson, William D ^a   Boughton, Clement R ^a   Robertson, Peter W ^a   Marinos, George ^a   Lloyd, Andrew R ^a,c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b Kirketon Road Center ^*  (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; VIRUS CHARACTERIZATION; VIRUS GENE;

EID: 0034686217     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2000.tb124124.x     Document Type: Article

References (23)

1. Crofts N, Jolley D, Kaldor J, et al. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997; 51: 692-697.
2. Australian National Council on AIDS and related diseases (ANCARD) Hepatitis C Subcommittee. Hepatitis C Virus Projections Working Group: estimates and projections of the hepatitis C virus epidemic in Australia. Sydney: National Centre in HIV Epidemiology and Clinical Research, 1998.
3. Shiell A, Brown S, Farrell GC. Hepatitis C: an economic evaluation of extended treatment with interferon. Med J Aust 1999; 171: 189-193.
4. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virology 1993; 74 Part II: 2391-2399.
5. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13-18.
6. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-639.
7. Simmonds P, Mellor J, Craxi A, et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatology 1996; 24: 517-524.
8. Berg T, Hopf U, Stark K, et al. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J Hepatology 1997; 26: 484-491.
9. Boughton CR, Hawkes RA. Viral hepatitis and the drug cult: a brief socio-epidemiological study in Sydney. Aust N Z J Med 1980; 10: 157-161.
10. van Beek I, Dwyer R, Dore GJ, et al. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ 1998; 317: 433-437.
11. Halfon P, Khiri H, Gerolami V, et al. Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA. J Hepatology 1996; 25: 307-311.
12. Bhattacherjee V, Prescott LE, Pike I, et al. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. J Gen Virology 1995; 76 Part 7: 1737-1748.
13. White P, Zhai X, Carter I, et al. Simplified hepatitis C virus genotyping using heteroduplex mobility analysis. J Clin Microbiology. In press.
14. Moaven LD, Crofts N, Locarnini SA. Hepatitis C virus infection in Victorian injecting drug users in 1971 [letter]. Med J Aust 1993; 158: 574.
15. Thomson JA, Rodger AJ, Thompson SC, et al. The prevalence of hepatitis C in patients admitted with acute hepatitis to Fairfield Infectious Diseases Hospital, 1971-1975. Med J Aust 1998; 169: 360-363.
16. Binotto E, Boughton CR, Hawkes R, et al. A serological and epidemiological re-evaluation of acute non-A non-B hepatitis from the early 1970s. Aust N Z J Med. In press.
17. MacDonald MA, Wodak AD, Dolan KA, et al. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Med J Aust 2000; 172: 57-61.
18. Lau JY, Mizokami M, Kolberg JA, et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995; 171: 281-289.
19. McCaw R, Moaven L, Locarnini SA, et al. Hepatitis C virus genotypes in Australia. J Viral Hepatitis 1997; 4: 351-357.
20. Kaba S, Dutta U, Byth K, et al. Molecular epidemiology of hepatitis C in Australia. J Gastroenterol Hepatol 1998; 13: 914-920.
21. Moaven LD, Crofts N, McCaw R, et al. The changing prevalence of hepatitis C virus types in injecting drug users between 1971 and 1994 [letter]. Med J Aust 1996; 165: 233.
22. Pol S, Thiers V, Nousbaum JB, et al. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995; 108: 581-583.
23. Rodger AJ, Thomson JA, Thompson SC, et al. Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: results of a pilot study [see comments]. J Gastroenterol Hepatol 1999; 14: 269-273.